Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review

Thyroid Research

Volumn 4, Issue 1, 2011, Pages

  Leung, Angela M ^a,c   Dave, Shalini ^b   Lee, Stephanie L ^a,c   Campion, Francis X ^c   Garber, Jeffrey R ^c,d   Pearce, Elizabeth N ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052762365     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-4-9     Document Type: Article

References (15)

1. An expanded view of risk-group definition in differentiated thyroid carcinoma. Cady B, Rossi R, Surgery 1998 104 947 10.1016/S0039-6060(98)70034-0
2. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Hay ID, Grant CS, Taylor WF, et al. Surgery 1987 102 1088 3686348
3. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Hay ID, Bergstralh EJ, Goellner JR, et al. Surgery 1993 114 1050 8256208
4. Prospective multicenter study of thyrois]carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Sherman SI, Brierley JD, Sperling M, et al. Cancer 1998 83 1012 10.1002/(SICI)1097-0142(19980901)83:5<1012::AID-CNCR28>3.0.CO;2-9 9731906
5. American Joint Committee on Cancer, Cancer Staging Manual Springer-Verlag 6 2002
6. Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values. Kloos RT, J Clin Endocrinol Metab 2010 12 5241 10.1210/jc.2010-1500
7. Serum thyroglobulin determination in thyroid cancer patients. Francis Z, Schlumberger M, Best Pract Res Clin Endocrinol Metab 2008 22 1039 10.1016/j.beem.2008.09.015 19041830
8. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Cooper DS, Doherty GM, Haugen BR, et al. Thyroid 2009 19 1167 10.1089/thy.2009.0110 19860577
9. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Mazzaferri EL, Jhiang SM, Am J Med 1994 97 418 10.1016/0002-9343(94)90321-2 7977430 (Pubitemid 24345593)
10. Management of low-risk differentiated thyroid cancer. Mazzaferri EL, Endocr Pract 2007 13 498 17872353
11. Management and outcome of recurrent well-differentiated thyroid carcinoma. Palme CE, Waseem Z, Raza SN, et al. Arch Otolaryngol Head Neck Surg 2004 130 819 10.1001/archotol.130.7.819 15262757 (Pubitemid 38915967)
12. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Mercante G, Frasoldati A, Pedroni C, et al. Thyroid 2009 19 707 10.1089/thy.2008.0270 19348581
13. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Lin HW, Bhattacharyya N, Laryngoscope 2009 119 1983 10.1002/lary.20617 19655332
14. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Orlov S, Orlov D, Shaytzag M, et al. Head Neck 2009 31 782 10.1002/hed.21020 19260133
15. Recurrence after treatment of micropapillary thyroid cancer. Ross DS, Litofsky D, Ain KB, et al. Thyroid 2009 19 1043 10.1089/thy.2008.0407 19772419